Reverse Merger - Summary of Pro Forma Results of Operation (Detail) - OncoGenex Pharmaceuticals, Inc [Member] - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	6 Months Ended
Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Business Acquisition [Line Items]
Net loss applicable to common shareholders	$ (4,747)	$ (3,163)	$ (7,769)	$ (6,637)
Net loss per share-basic and diluted	$ (3.10)	$ (11.50)	$ (5.59)	$ (24.08)
Weighted average shares	1,529,532	275,093	1,389,209	275,612

The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(3)
-URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463

Name:	us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration